Suven Life Sciences
announces top-line results from its Phase 2A proof of concept study evaluating the efficacy, safety and tolerability of Masupirdine (SUVN-502). The first of its kind trial which focused on advanced stage AD patients (moderate AD) who are currently treated with standard of care Donepezil and Memantine. The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.
The primary efficacy endpoint of the trial is changed from baseline to Week 26 in ADAS-Cog 11 score. The secondary outcome measures are MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, safety and tolerability assessment.
“We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502),” Venkat Jasti, CEO of Suven said.
Suven Life Sciences Ltd is currently trading at Rs264.90 down by Rs49.9 or 15.85% from its previous closing of Rs314.80 on the BSE.